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Background: Persons who inject drugs (PWID) are at an elevated risk for human immunodeficiency virus (HIV) and
hepatitis C virus (HCV) infection. In many high-income countries, needle and syringe exchange programs (NSP)
have been associated with reductions in blood-borne infections. However, we do not have a good understanding
of the effectiveness of NSP in low/middle-income and transitional-economy countries.
Methods: A systematic literature review based on PRISMA guidelines was utilized to collect primary study data on
coverage of NSP programs and changes in HIV and HCV infection over time among PWID in low-and middle-
income and transitional countries (LMICs). Included studies reported laboratory measures of either HIV or HCV and
at least 50% coverage of the local injecting population (through direct use or through secondary exchange). We
also included national reports on newly reported HIV cases for countries that had national level data for PWID in
conjunction with NSP scale-up and implementation.
Results: Studies of 11 NSPs with high-coverage from Bangladesh, Brazil, China, Estonia, Iran, Lithuania, Taiwan,
Thailand and Vietnam were included in the review. In five studies HIV prevalence decreased (range −3% to −15%)
and in three studies HCV prevalence decreased (range −4.2% to −10.2%). In two studies HIV prevalence increased
(range +5.6% to +14.8%). HCV incidence remained stable in one study. Of the four national reports of newly
reported HIV cases, three reported decreases during NSP expansion, ranging from −30% to −93.3%, while one
national report documented an increase in cases (+37.6%). Estimated incidence among new injectors decreased in
three studies, with reductions ranging from −11/100 person years at risk to −16/100 person years at risk.
Conclusions: While not fully consistent, the data generally support the effectiveness of NSP in reducing HIV and
HCV infection in low/middle-income and transitional-economy countries. If high coverage is achieved, NSP appear
to be as effective in LMICs as in high-income countries. Additional monitoring and evaluation research is needed
for NSPs where reductions in HIV/HCV infection among PWID are not occurring in order to identify and correct
contributing problems.
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Human immunodeficiency virus (HIV) and hepatitis C
(HCV) are relatively efficiently transmitted through the
multi-person use (sharing) of needles and syringes used
for injecting illicit psychoactive drugs [1,2]. There are an
estimated 16 million people who inject drugs (PWID) in
the world, of whom 13 million live in low and middle-
income countries (LMIC) [3]. PWID who live in LMIC
are generally at very high risk for infection with HIV and
HCV. High rates of HIV prevalence (>20%) have been
reported among PWID in Eastern Europe, Asia and
Africa [3].
Programs to provide PWID with access to sterile nee-
dles and syringes (NSPs) are generally considered to be
among the most effective means of reducing HIV and
HCV transmission among PWID [4,5]. There is a con-
siderable body of research on NSP, and syringe exchange
programs in particular. There is general consensus that
these programs reduce risk behavior [6] (sharing of nee-
dles and syringes) and large-scale implementation of
NSP has been associated with reductions in transmission
of HIV [7]. The great majority of studies of syringe ex-
change programs, however, have been conducted in
high-income countries. For example, in a Palmateer
et al. review [8], 144 of the 152 included studies were
conducted in high-income countries.
There are a number of reasons why NSP may not be
as effective in low/middle-income countries as in high-
income countries. First, LMIC may not have the financial
resources or the public health and non-governmental
organizational infrastructure for successful large-scale im-
plementation of NSP. Second, PWID in LMIC may face
greater stigmatization, leading to less utilization of the
programs in LMIC [9]. Third, there may be greater law
enforcement interference with PWID utilizing syringe ex-
change programs in LMIC, particularly in locations where
PWID may be incarcerated in “detention” centers or in
locations where they may suffer extortion or brutality
from the police [10]. Finally, NSP in high-income settings
may be implemented in the context of other large scale
evidence-based HIV/HCV-related prevention programs
such as opiate substitution therapy/medication-assisted
treatment [11]. The NSPs in high-income countries may
thus benefit from the synergistic effects of “combined”
prevention programming [12,13]. In contrast, NSP in
LMIC are often implemented either by themselves or in
the presence of other prevention programs that exist only
on a pilot project scale [14].
Given the great need to reduce HIV transmission
among PWID in many LMIC, and the potential barriers
to the effectiveness of programs in these countries,
understanding what has happened with the programs
that have been implemented is likely to be critical for
efforts in halting ongoing HIV epidemic among PWID.In this review, we examine structural level NSP in dif-
ferent LMIC around the world to determine if imple-
mentation and scale up of NSP are associated with
longitudinal changes in blood borne infection among
PWID populations. By focusing on locations where NSP
have been implemented and scaled compared with loca-
tions in which NSP have already been established, this
review can help to elucidate the association between
NSP implementation and changes in HIV/HCV preva-
lence and/or incidence among the PWID population
served by the NSP.
Methods
Unit of analysis and eligibility criteria
The unit of analysis for this review was a NSP in a spe-
cific location. In our search for eligible programs, we
attempted to collect as much information as possible,
including published and unpublished articles, conference
presentations, and “gray” literature. This differs from
the usual systematic review where individual research
reports or individual research studies are the standard
unit of analysis. To be included in this review, the NSP
had to have reached a coverage level of 50% or more of
the PWID in the local population (through either direct
service provision or secondary exchange, in which PWID
receive syringes from NSP and distribute to their PWID
peers) and provide at least 10 syringes per injector per
year. This size criterion was used to distinguish between
high coverage from programs that were “demonstration
projects” or “pilot studies.” This level has also been
shown to be an adequate coverage level to influence
population level changes in rates of HIV and HCV infec-
tion [15,16]. The amount of time that was needed for
each NSP to achieve structural level coverage varied;
however, many of the studies achieved 50% coverage
shortly after implementation, and by the follow-up bio-
marker measurement, all NSP had achieved structural
level coverage of their PWID.
To include a specific program in the review, we
located data on when the program was implemented, in-
cluding when it reached the minimum size requirement,
and located data on either HIV/HCV prevalence or inci-
dence from before and after implementation of the NSP
program. We required that the HIV or HCV-related data
be based on laboratory testing, not on self-reported ser-
ostatus. Studies that used self-reported behavior change
as their outcome measure were not included because of
concerns for social desirability effects and the often im-
precise association between behavior change and change
in HIV/HCV infection rates [17].
A wide variety of research designs were included: ran-
domized clinical trials, time series analyses, cohort stud-
ies, comparisons of injecting populations that received
NSP with “comparable” injecting populations that did
F1
Search String
Search (randomized controlled trial[pt,  #108] OR controlled clinical trial[pt,  #108] OR randomized 
controlled trials[mh,  #813] OR random allocation[mh,  #813] OR double-blind method[mh,  #813]
OR single-blind method[mh,  #813] OR clinical trial[pt,  #108] OR clinical trials[mh,  #813] OR 
("clinical trial"[tw]) OR ((singl*[tw] OR doubl*[tw] OR trebl*[tw] OR tripl*[tw]) AND (mask*[tw] 
OR blind*[tw])) OR placebos[mh,  #813] OR placebo*[tw] OR random*[tw] OR non-randomi*[tw] 
OR before after study[tw] OR time series[tw] OR case control[tw] OR prospective cohort[tw] OR 
retrospective cohort[tw] OR cross-section*[tw] OR prospective[tw] OR retrospective[tw] OR 
research design [mh:noexp] OR comparative study[mh,  #813] OR evaluation studies[mh,  #813] OR 
follow-up studies[mh,  #813] OR prospective studies[mh,  #813] OR control*[tw] OR 
prospectiv*[tw] OR volunteer*[tw] OR longitud*[tw] OR descripti*[title/abstract] OR 
study[title/abstract] OR evaluat*[title/abstract]) AND
Search (HIV Infections/prevention and control[MeSH] OR HIV[MeSH] OR hiv[tw] OR hiv-1[tw] 
OR hiv-2*[tw] OR hiv1[tw] OR hiv2[tw] OR hiv infect*[tw] OR human immunodeficiency virus[tw] 
OR human immune deficiency virus[tw] OR human immuno-deficiency virus[tw] OR human 
immune-deficiency virus[tw] OR ((human immun*) AND (deficiency virus[tw])) OR acquired 
immunodeficiency syndromes[tw] OR acquired immune deficiency syndrome[tw] OR acquired 
immuno-deficiency syndrome[tw] OR acquired immune-deficiency syndrome[tw] OR ((acquired 
immun*) AND (deficiency syndrome[tw])) OR (Hepatitis C/prevention and control[Mesh] OR 
hepatitis C[tw] OR hepatitis[title/abstract] OR HCV[title/abstract]) AND
Search (needle-exchange[title/abstract] OR needle exchange[title/abstract] OR needle/syringe 
program[title/abstract] OR needle/syringe programs[title/abstract] OR needle syringe[title/abstract] 
OR (needle[title/abstract] AND syringe[title/abstract]) OR needle/syringe program*[title/abstract] 
OR syringe-exchange[title/abstract] OR syringe exchange*[title/abstract] OR 
(supervis*[title/abstract] AND injecti*[title/abstract]) OR Combined program*[title/abstract] OR 
Combined prevention[title/abstract]) OR (needle*[title/abstract] AND access[title/abstract]) OR 
(syringe*[title/abstract] AND access[title/abstract]) OR ((injection drug user*[title/abstract] OR 
injecting drug user*[title/abstract] OR IDU[title/abstract]) AND pharmacy[title/abstract] OR 
pharmacies[title/abstract] OR dispensar*[title/abstract] OR chemist[title/abstract] OR 
chemists[title/abstract] OR apothecar*[title/abstract]) AND
Search (Needle-Exchange Programs[Mesh] OR Needle-Exchange Programs/legislation and 
jurisprudence[Mesh] OR Community Health Services[Mesh] OR Substance Abuse, 
Intravenous/prevention and control[Mesh] OR Health Policy[Mesh] OR Harm reduction[Mesh] OR 
Public health administration[Mesh] OR Regional health planning[Mesh] OR Preventive Health 
Services[Mesh] OR Local Government[Mesh] OR Government Agencies[Mesh] OR Community 
Health Planning[Mesh] OR Community Health Centers[Mesh] OR Program Evaluation[Mesh] OR 
Socioeconomic factors[Mesh] OR Delivery of Health Care[Mesh] OR Community Pharmacy 
Services/legislation and jurisprudence[Mesh] OR Legislation, Pharmacy[Mesh] OR structural 
intervention*[tw] OR politic*[title/abstract] OR community[title/abstract] OR region*[title/abstract] 
OR government[title/abstract] OR legislat*[title/abstract] OR law[title/abstract] OR 
policy[title/abstract] OR (structural[tw] AND intervention[tw]) OR (structural[title/abstract] AND 
intervention[title/abstract]))
Figure 1 Search terms and terminology used for retrieval of eligible citations and reports. This figure displays the terminology used to search
for relevant studies. Keyword and subject terms were retrieved from previous research of systematic reviews on similar HIV/HCV topics among PWID.
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iety of research designs, including many that do not
permit strong inferences about causation, were included
in order to capture as many studies as possible. Pro-
grams for which we were able to locate data only after
full NSP implementation were not included in the
review.
Finally, the studies included had to come from loca-
tions defined by the World Bank as low/middle-income
countries or transitional-economy countries [18]. Studies
from high-income locations were screened by research-
ers, but not included in this review.
Search methodology
Selection of studies for this review was based on a struc-
tured literature review and analysis utilizing Preferred
Reporting items for Systematic Reviews and Meta-
Analysis (PRISMA) guidelines [19,20]. Systematic litera-
ture searches were conducted to identify potentially
eligible articles from journals and government/countryreports. Figure 1 describes in detail the search terms that
were utilized for this review; the same search terminology
was used for each of the databases searched, which
included PubMed, EMBASE, Web of Science, and NLM
Gateway. In addition, we also searched conference
abstracts from International AIDS Conferences (IAC)
from 2000 through 2011 and International Harm Reduc-
tion conferences (IHRA) from 2000 through 2011 [21],
along with published reviews of needle and syringe ex-
change programs throughout the world. For locations in
which HIV or HCV information was available but
coverage information was not consistent (such as in
Bangladesh and Vietnam), we contacted researchers
via email with knowledge of the programs in each lo-
cation to obtain the necessary coverage information if
available, including the number of PWID that visit
the NSP, the number of needles/syringes distributed,
and the number of PWID that are covered by the
NSP. The search included all studies published be-
tween January 1st 1980 and November 30th 2011.
F2
Des Jarlais et al. BMC Public Health 2013, 13:53 Page 4 of 13
http://www.biomedcentral.com/1471-2458/13/53Data abstraction and coding
A standardized coding form was developed to document
pertinent information for each program. Information
collected included demographics of the injecting popula-
tion covered under the NSP, characteristics of the NSP
including coverage and distribution information, and in-
formation related to changes in HIV or HCV infections
over time. If analysis of HIV or HCV infection data was
conducted on specific subgroups (such as by age, race,
gender, etc.) these data were collected as well. In
addition, we reported measures of changes in subgroups
or from multivariate modeling if studies reported effects
with adjustment for participant characteristics in relation
to changes in HIV or HCV infection information over
time.
Studies were independently coded by two research
associates (JF and SM). All coding forms were reviewed
for quality by the co-principal investigator (HH) before
finalization, with disagreements in coding reviewed by
the principal investigator (DDJ).
In locations where multiple studies described the same
NSP intervention, we compiled data across studies, fo-
cusing on the most complete measures of exposure to
the NSP intervention with the most comprehensive re-
view of HIV/HCV information including effect modi-
fiers, adjustment for confounders, and length of the
evaluation. We also combined data from multiple studies
of the same intervention if different aspects of the data
we needed were in different reports, e.g., number of
PWID in one report and numbers of syringes exchanged
in a different report.
Types of interventions
We were prepared to include both syringe exchange pro-
grams and increased pharmacy sales programs as NSPs.
However, all of the programs for which we were able to
obtain the necessary data (see inclusion criteria above)
were needle and syringe exchange programs.
Types of outcome measures
The primary outcomes of interest in this review include
changes in prevalence or incidence of HIV, HCV, HIV/
HCV co-infection or changes over time in newly
reported HIV or HCV cases of infection. For studies that
reported these measures for a specific subgroup, such as
new injectors vs. older injectors, race, age, ethnicity, lo-
cation, or length of injecting career, these data were
recorded as well. For studies that included multivariate
modeling, adjusted effect sizes were presented if they
were based on changes in HIV or HCV infection data
among PWID over time. Several studies used HIV
prevalence among new injectors to estimate HIV inci-
dence among new injectors, and we also included those
data.Analysis of included studies
We performed a systematic review of the effects of ex-
posure to NSP on incidence or prevalence of HIV and
HCV infections among PWID in selected locations. A
quantitative synthesis was not conducted due to the
considerable variations in time period of analyses, mea-
sures of effect size, non-comparable study designs, the
specific operating characteristics of the programs, and
uncertain bias across and between studies due to lack of
randomization. A narrative analysis permits reviewing of
selected issues, cases, or events in depth identified
through the systematic review [22], allowing for a more
complete and detailed analyses not constrained by pre-
determined categories.Results
Description of search results
Figure 2 displays the systematic search of the literature.
Four domains were included in the search terms, includ-
ing NSP terminology, pharmacy terminology, biomarker
terminology (HIV, HCV), and finally study design ter-
minology. The original search comprised 1,291 citations
from a systematic search reviewed by two reviewers in-
dependently (JF and SM) after removal of duplicate
records not identified through the systematic import-
ation of eligible studies from each database (NLM
Gateway, PubMed, Web of Science, and EMBASE). Add-
itionally, we performed a secondary search of needle and
syringe exchange program papers utilizing reference lists
from systematic review of NSP programs [8,23,24] and
through collaboration with experts in the field of injec-
tion drug use in low/middle and transitional income
locations. An additional 570 articles/reports were obtained
and reviewed, and we identified an additional nine studies
from this secondary search after removal of duplicates from
the secondary search. A total of 66 full text articles were
examined, and 11 qualitative studies and reports were
obtained from this full text search.Results of the search
A total of 11 studies/reports examining nine low/mid-
dle-income or transitional-economy countries were eli-
gible for inclusion in this NSP review based on
laboratory HIV or HCV results and greater than 50%
coverage of the NSP within the respective community.
These 11 studies described 12 distinct locations involv-
ing NSP evaluated from 1990 through 2010. If multiple
locations in a single country were examined the data are
presented by location and by time period. Studies
included in this review cover locations in Bangladesh,




2045 Records identified through  
database searching
1861 Records after duplicates  
removed
66 Full-text articles assessed for  
eligibility
11 Studies included in qualitative  
synthesis
9 Records identified from National  
Reports
1861 Records screened 
55 Full-text articles excluded due to: 
•Did not describe structural 
intervention
•Biomarker data not presented
•Longitudinal data not available
•Sample is not all PWID
•Study did not come from a low or 
middle Income country
Figure 2 PRISMA diagram of eligible studies included in review. This figure displays the methodology of review of literature from databases
included in the review. The PRISMA diagram outlines how the research team arrived at the eligible study list utilized in this review.
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There were six studies that documented population level
changes in HIV prevalence over time and three studies
that documented population level changes in HCV in-
fection prevalence or incidence over time. Of the six
studies reporting on HIV prevalence, four studies reported
population level decreases in prevalence ranging from
−3% to −15% while two studies reported population level
increases ranging from +6% to +16%. Of the three studies
reporting on population level HCV infection prevalence
or incidence, all reported decreases in prevalence ranging
from −4.2% to −10.1%, while one study reported a stable
population level incidence of 1.2-1.3/100 person years
(PY). Estimated HIV incidence among new PWID
(defined as less than three years of injecting history)
decreased in three studies ranging from −16/100 PY to
−11/100PY. Table 1 summarizes the HIV and HCV infec-
tion prevalence/incidence studies included in the review.
National surveillance reports were evaluated for
changes in newly reported HIV cases during NSP expan-
sion in Iran, Taiwan, Lithuania and Vietnam. Reportsfrom Iran, Taiwan and Vietnam reported decreases in
newly reported HIV cases, ranging from −30% to −93.3%.
Lithuania reported an increase of +37.6% in newly reported
HIV cases among PWID. Table 2 summarizes the changes
in newly reported HIV cases among PWID during imple-
mentation of NSP services.
Included studies
There were nine primary research articles included in this
review: Azim 2008 [28], Azim 2009 [29], Caiaffa 2003 [26],
Wu 2007 [27], Hammett 2006 [36], Des Jarlais 2007 [37]
and Hammett 2012 [31], Uuskula 2011 [30], and Gray
1998 [25]. Additionally, there were four national surveil-
lance reports included: Iranian MOH 2007 [32], Astraus-
kiene 2010 (Lithuania) [33], CDC 2010 (Taiwan) [34], and
Hammett 2012 (Vietnam) [35].
Primary study interventions
Dhaka Bangladesh
In Bangladesh, NSP were expanded significantly starting
in 1998 with full implementation occurring in 2000. By
Table 1 Summary of primary studies with HIV/HCV biomarkers
Study Information Coverage Pre-Implementation and Expansion Post-Implementation and Expansion


















150-160 1993 46 33% 1996 132 18% (15%)
Caiaffa 2003 [26] Porto Alegre, Brazil Pre-Post Study
Comparison
6-20 1998 137 49% 2001 255 64.3%
(+16%)
Wu 2007 [27] Dagou, China Pre-Post Study
Comparison
290-300 2002 235 40% 99% 2003 226 34% (6%) 89% (10%)
Luzhai, China Pre-Post Study
Comparison
140-150 2002 194 56% 89% 2003 219 53% (3%) 85% (4%)
Azim 2008 [28] Dhaka, Bangladesh Time Series Cross
Sectional
285-344 1990 418 2% 67% 2006 1092 7% (+5%) 57% (10%)
Azim 2009 [29] Dhaka, Bangladesh Time Series Cross
Sectional




Uuskula 2011 [30] Tallinn, Estonia Time Series Cross
Sectional
23-78 2005 350 54% 20.9/100
PY
2009 327 50% (4%) 9/100 PY
Hammett 2012
[31]
Ning Ming, China Time Series Cross
Sectional
20-30 2002 290 17% 12/100 PY 2008 187 11% (6%) 11/100 PY
Lang Son, Vietnam Time Series Cross
Sectional
20-30 2002 342 46% 22/100 PY 2009 185 23% (23%) 3/100 PY
1. Syringes per PWID/Year are given as a range based on the first and last date of data collection in each primary study location.
2. Among new PWID (persons who had begun injecting in the previous 3 years, assumed to be HIV negative when they began injecting).





















Table 2 Summary of National Surveillance Data of HIV Biomarkers
Country Report Information Coverage Pre Implementation and Expansion Post Implementation and Expansion
Investigators Location Surveillance Method Syringes per PWID/Year1 Year Baseline HIV cases (n) Year Follow-up2 HIV cases (n) (Percent Change)
CDC 2007 [32] Iran National Surveillance Data 4-41 2003 2332 2007 426 (82%)
Astrauskiene 2010 [33] Lithuania National Surveillance Data 56-98 2005 85 2009 117 (+38%)
CDC 2010 [34] Taiwan National Surveillance Data 7-67 2006 1693 2010 114 (93%)
Hammett 2010 [35] Vietnam National Surveillance Data 9-52 2005 11358 2009 7947 (30%)
1. Syringes per PWID/Year are given as a range based on the first and last date of data collection in respective study.
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ered 89-93% of the PWID in Dhaka, and distributed up
to three syringes and six needles per injector per week
with an average needle and syringe exchange rate of 73%
among program participants [28].
Azim 2008 [28] and Azim 2009 [29] recruited male
PWID from NSP, detoxification centers, and clinics in
Dhaka, Bangladesh to analyze prevalence and incidence
of HIV and HCV infection. Azim 2008 [28] examined
3,759 male PWID from 1999–2006 and documented an
HIV prevalence increase from 1.4% (1999–2000) to 7%
(2006). HCV infection prevalence decreased from 66.5%
(1999–2000) to 56.4% (2006).
Azim 2009 [29] analyzed PWID HIV incidence from
1998–2007. The HIV incidence among PWID remained
stable at 1.16/100 PY (1998–1999) to 1.29/100 PY (2007)
while HCV infection incidence among PWID decreased
from 37.50/100 PY (1998–1999) to 11.58/100 PY (2007).
Azim 2009 reported decreases in several injection
related behaviors; borrowing of needles/syringes decreased
10.6% while lending of needles/syringes decreased 29.8%.
Additionally, long term PWID were more likely to utilize
the NSP; those who had at least a 10 year history of injec-
tion drug use were nearly three times more likely to utilize
the NSP compared to PWID who had been injecting for
less than 10 years.
Porto Alegre Brazil
NSP programs in Porto Alegre were started in 1996 with
cooperation from the public health system in conjunc-
tion with municipal and state authorities. In 1998, the
NSP program distributed approximately 48,000 needles/
syringes, increasing to over 150,000 in 2002 with an ex-
change rate of nearly 50%; the NSP serve a population of
approximately 7,000 to 8,000 PWID.
Caiaffa 2003 [26] recruited PWID from non-institutio-
nalized locations in Porto Alegre in 1998 (when NSP
was still in its scale up and expansion period), and again
in 2000–2001 (when NSP had become fully established
in the city). PWID in both samples were predominately
young (average age: 28–31 years old), male (81-84%),
and injected mainly cocaine (74-87%). Both samples had
moderate to high levels of sharing in the last six months
(36-59%), and 60% had ever visited the NSP at least
once. HIV prevalence among PWID in Porto Alegre
during NSP implementation increased from 48.5%
(1998) to 64.3% (2000–2001). No explanation was given
by authors related to the changes in HIV infection
prevalence seen among locations without NSP in place.
Dagou & Luzhai China
In 1998 the Ministry of Health of China promoted social
marketing of safe injection as part of their HIV/AIDS
prevention strategy. The first NSP were started in Dagouand Luzhai with ramp up beginning in 2002. The num-
ber of NSP locations in China increased from 93 sites in
March 2006 to 729 by December 2006.
Wu 2007 [27] analyzed the impact of NSP on HIV
prevalence in Dagou and Luzhai and compared results
to two cities in China that did not have NSP programs
in place, Yu’nan and Yongning. PWID were recruited
into the study from several locations including detoxifi-
cation centers and community outreach. In all four loca-
tions in which PWID were recruited (Dagou, Luzhai,
Yu’nan, and Yongning), PWID were predominantly male
and between 20 and 39 years of age.
Both locations that had NSP documented decreases in
HIV and HCV infection prevalence. In Dagou, HIV
prevalence decreased from 40% (2002) to 33.6% (2003)
(p = 0.16), while HCV infection prevalence decreased
from 98.7% (2002) to 88.5% (2003) (p < 0.01). In Luzhai,
HIV prevalence decreased from 56.2% (2002) to 53.2%
(2003) (p = 0.54), while HCV infection prevalence
decreased from 88.7% (2002) to 84.5% (2003) (p = 0.22).
In the cities that did not have NSP in place, changes in
HIV and HCV infection prevalence varied. In Yu’nan,
HIV prevalence remained stable at 17.6% (2002–2003)
(p = 0.99), while HCV prevalence decreased from 88.1%
(2002) to 58.5% (2003) (p < 0.01). In Yongning HIV
prevalence increased from 22.4% (2002) to 24.1% (2004)
(p = 0.68) while HCV infection prevalence increased
from 81.6% (2002) to 88.2% (2004) (p = 0.07). No ex-
planation was given by authors related to the changes
seen in HIV and HCV infection prevalence seen among
locations without NSP in place.
Lang Son Province Vietnam & Ning Ming County China
The “Cross-Border” intervention took place in the regions
of Lang Son Province, Vietnam and Ning Ming County in
the Guangxi province in China. The intervention involved
packaged harm reduction services, including a pharmacy-
based voucher program for acquiring clean needles/syr-
inges along with clean injecting equipment and condoms.
On average, 7,000 to 10,000 needles/syringes were distrib-
uted per month at each location, serving a population of
approximately 3,000 PWID in each region. Three studies
reported on changes in HIV prevalence in these locations,
Hammett 2006 [36], Des Jarlais 2007 [37] and Hammett
2012 [31]; this review includes the more complete analysis
utilizing a longer follow-up period from Hammett 2012.
Hammett 2012 [31] documented changes in HIV preva-
lence and HIV incidence among new PWID over an eight
year period in conjunction with NSP expansion in both
locations beginning in 2002 of which six years of data was
available for Ning Ming while seven years of data was
available for Lang Son. 2125 PWID were included in the
Ning Ming sample and 2677 PWID were included in the
Lang Son sample.
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14% after 12 months, and then stabilized at 11% after
72 months (p = 0.003). In Lang Son, HIV prevalence
decreased to 43% after 12 months and decreased further
to 23% after 84 months (p < 0.001). When examining only
new PWID, defined as injectors that had injected for three
years or less, HIV incidence in Ning Ming decreased from
12/100 PY to 9/100 PY after 12 months and stabilized
at 11/100 PY after 72 months. Among new PWID in Lang
Son the HIV incidence decreased from 22/100 PY to
16/100 PY after 12 months and decreased further to 3/100
PY after 84 months (p < 0.001).Tallinn Estonia
NSP was implemented in Estonia in 2003 with the ma-
jority of services provided in the capital city of Tallinn,
where nearly 75% of the PWID in Estonia are located.
The NSP serve a population of approximately 10,000
PWID and have increased needle/syringe distribution
greatly since implementation, from 18,000 needles/syr-
inges distributed in 2003 to over 770,000 by 2009.
Uusküla 2011 [30] recruited 1,027 PWID between
2005 and 2009, of which 168 were new injectors (defined
as having injecting histories of three years or less). The
sample was predominately male (80%), Russian (80%),
and young (mean ages: 24 to 27 years old). Among new
injectors, subjects were predominately male (74-82%),
Russian ethnicity (78-89%), and mainly injected fentanyl
(48-61%) or amphetamine (32-47%). High levels of re-
ceptive needle/syringe sharing were documented among
new PWID, with rates ranging from 74-79%.
HIV prevalence in the entire sample decreased slightly
from 54% (2005) to 50% (2009). However, when examin-
ing only new injectors, HIV prevalence decreased from
34.2% (2005) to 15.8% (2009) (p = 0.046); after control-
ling for age, gender, injection frequency and NSP use,
the change in overall HIV prevalence among new injec-
tors remained statistically significant (χ2 = 8.31, p =
0.016). Estimated HIV incidence among new injectors
decreased from 20.9/100 PY (2005) to 9/100 PY (2009)
(p = 0.026).
Several injection-related behaviors were measured in
the study among the PWID sample; during the study
period, receptive sharing of needles/syringes decreased
5% and the percentage of injectors that utilized NSP
increased from 44% in 2005 to 76% in 2009.Chiang Rai Thailand
The NSP in Chiang Rai Province Thailand originally
began in 1992 in three of the nine Akha hill tribe villages
in northern Thailand. Five thousand needle and syringe
kits were provided by the government for vaccination
and were subsequently distributed among 46 PWID inthree villages from 1992 to May 1994. During the period
of evaluation, needles were not allowed to be distributed
for the purposes of needle exchange; however, there was
an agreement made that allowed for this small village to
receive needles and syringes in response to the elevated
number of new infections among PWID in the hill tribe
villages. In 1995 a grant from the Australian government
allowed implementation of NSP in all nine villages. The
NSP served approximately 132 PWID and allowed up to
12 needles/syringes to be acquired per month for each
PWID.
Gray 1998 [25] analyzed the impact of the NSP on
HIV prevalence among PWID in Akha hill tribe villages
in Chiang Rai Province Thailand from 1993–1996. All
PWID in this location were included in the study; 46
were part of the 1993–1994 sample while 132 were part
of the follow-up 1995–96 sample. The samples were typ-
ically male (85%) and injected primarily heroin.
Over the course of the study, the HIV prevalence
among PWID decreased from 33% (1993) to 18% (1995–
1996).
National surveillance report interventions
Islamic Republic of Iran
The first NSP in the Islamic Republic of Iran was estab-
lished in 2003 [32]. Programs slowly increased after
2003 as laws were reformed so PWID were not arrested
if they were covered by prevention and care services in-
cluding drop-in centers which offer NSP [38]. In 2007
there were 4,665,512 needles/syringes distributed, with
an average of 41 needles/syringes distributed per PWID
per year; during the same time period NSP sites
increased from 170 in 2008 to 637 by 2010 [21].
The Center for Disease Management at the Iranian
Ministry of Health reported national surveillance data
on annual newly reported cases of HIV among PWID
undergoing testing at surveillance sites from 1986 to
2007. The number of newly reported cases among PWID
continued to increase through the late 1990s and early
2000s with 2332 cases in 2003, and a peak of 3145 new
cases in 2004. However, with the implementation and
scale-up of NSP services, the number of newly reported
cases among PWID began to drop to 2,293 cases in
2005, 1,658 cases in 2006, and 426 cases in 2007.
Lithuania
In early 1997 NSP was first introduced in Lithuania via
mobile and illegal underground needle/syringe distribu-
tion. In 2006 NSP was legalized in Lithuania, and by
2009, there were 12 NSP sites in Lithuania serving ap-
proximately 3,200 PWID. The number of needles/syr-
inges distributed increased starting in 2006 and by 2008
313,000 needle/syringes were distributed to PWID, de-
creasing to 188,000 in 2009. No explanation was given
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Astrauskiene 2010 [33] reported national newly
reported HIV cases among PWID, collected by the Min-
istry of Health of Lithuania. The number of newly
reported HIV infections among PWID decreased from
85 cases in 2005 to 62 cases in 2006, 59 cases in 2007,
and 42 cases in 2008. However, in 2009, there was an in-
crease with 117 newly reported cases among PWID. The
increase in cases in 2009 coincided with a significant de-
crease (40%) in needle/syringe distribution.
Taiwan
In 2005, Taiwan instituted NSP on a trial basis through-
out the country. By 2006 NSP in Taiwan had ramped up
to full-scale operation with a 900% increase in coverage
of PWID during the first two years of operation. A total
of 450,000 needles/syringes were distributed in the first
year, expanding to nearly four million in 2007, serving
approximately 60,000 PWID.
A 2010 Taiwan Center for Disease Control (CDC) [34]
document reported national surveillance data of newly
reported HIV cases among PWID. Surveillance data cap-
tured in this analysis include all HIV incident PWID
cases registered with CDC Taiwan between 2006 and
2010. The number of newly reported HIV cases among
PWID decreased from 1,693 cases in 2006 to 114 cases
in 2010.
Vietnam
NSP programs in Vietnam were started as pilot projects
in 1993, with major scale-up occurring in 2005 as a re-
sult of the HIV Prevention Project implemented by the
World Bank. In 2006, HIV/AIDS law mandated harm re-
duction activities that included NSP, leading to expan-
sion from 21 provinces in 2005 to over 60 provinces by
2009. During this same time period, the number of nee-
dles/syringes distributed increased from two million in
2006 to over 11 million in 2007, serving approximately
215,000 PWID.
Vietnam surveillance data among at risk groups col-
lected newly reported HIV cases from 2005 through
2009, coinciding with the period of expanding NSP in
the country [35]. During this time period, the number of
HIV cases among PWID decreased from 11,358 in 2005
to 7,947 cases in 2009.
Discussion
Before considering the substantive findings, it will be
useful to consider limitations on the quantity and quality
of the data on NSPs in low-and middle-income coun-
tries. As noted in the introduction, previous systematic
reviews of NSPs in LMICs included only two programs,
while we were able to locate data from 11 programs,despite stricter eligibility criteria such as biological mea-
sures of HIV or HCV as outcomes. Still, that we were
able to obtain the needed information for only a modest
number of NSP in LMICs raises concerns. Given our
difficulties in finding data on NSPs in LMICs, we have
to conclude that that the NSPs included in our system-
atic review probably do not reflect typical operations of
NSPs in low/middle-income countries. As programs
with better implementation are probably more likely
to report data, it is likely that the data included in
our review probably reflect NSPs with better reporting
mechanisms, supportive policies, or program operations
than “average.”
The data for the programs included in this study often
had considerable imprecision and variability. Coverage
in terms of the percentage of PWID who were reached
or the numbers of syringes exchanged per PWID per
year was often quite imprecise, as the estimates of PWID
in the local area often had very wide ranges, and the
numbers of syringes exchanged was sometimes reported
as a range rather than a simple count.
Another aspect of imprecision in the data comes from
using changes in HIV and/or HCV infection prevalence
and newly reported HIV cases among PWID as outcome
measures. Changes in HIV or HCV infection incidence
would be the most desirable outcome measure, but are
quite difficult to measure for both practical and ethical
reasons. An ethically conducted cohort study would need
to provide good access to sterile injection equipment to
subjects and thus may not reflect HIV or HCV infection
incidence in the local PWID population. Estimating HIV
incidence from HIV prevalence among new injectors
requires the assumption new injectors were HIV seronega-
tive when they began injecting, which is may not be valid
if there is substantial sexual transmission in the local area.
Changes in HIV/HCV co-infection prevalence reflect both
changes in the rate of new infections and differential loss
of HIV/HCV-infected versus HIV/HCV-uninfected per-
sons in the local population. (It is likely that more HIV
seropositives will be lost from the active injecting popula-
tion than HIV-negatives due to HIV-related morbidity and
mortality). Changes in the numbers of newly-diagnosed
HIV infections among PWID also have limitations as an
outcome measures. They may reflect changes in surveil-
lance methods and even if the surveillance methods do
not change, the time between when a new HIV infection
occurs and when it is reported may be substantial and the
reporting lag may itself change over time. We did not for-
mally grade the quality of the data in the different studies,
as there typically was not sufficient detail reported in the
studies for differentiating data quality among these studies.
It is our impression, however, that there was no relation-
ship between the quality of the data and the size of the de-
cline in HIV or HCV prevalence across the studies.
Des Jarlais et al. BMC Public Health 2013, 13:53 Page 11 of 13
http://www.biomedcentral.com/1471-2458/13/53Additionally, most of the changes in HIV/HCV infec-
tion incidence or prevalence in the studies reported here
also suffer from the lack of any comparison group.
All of these methodological limitations are likely to
persist in assessing the effectiveness of large-scale NSP for
HIV prevention among PWID. Communities are the ap-
propriate unit of analysis for assessing implementation of
high coverage NSP programs, so any studies with compari-
son groups would have to be very large and would likely be
logistically complex. Also, given the current data on the ef-
fectiveness of NSPs, it would be unethical to fail to provide
NSPs to PWID simply for the sake of conducting research.
Interpretation
Despite the limited quantity of data on NSPs in low-and
middle-income countries, we do believe that the data pre-
sented here can be used to address three critical questions
about NSPs in LMICs.
1. Is there a “critical coverage” level of syringe distri-
bution and PWID in NSP to affect change in HIV or
HCV infection incidence or prevalence? The numbers of
syringes distributed per PWID per year varied greatly
among the studies reported here, and there are only a
modest number of studies. Nevertheless, the data pre-
sented in Table 1 suggest that 20–30 syringes per year
per PWID might be considered a minimum level of
coverage that would lead to population-level effects
among opiate-using populations [16]. Note that in the
Porto Alegre study, only 20 syringes were distributed per
PWID per year, and cocaine was the primary drug
injected. As cocaine is often injected at very high fre-
quencies, it is likely that more syringes per PWID per
year are needed to control HIV transmission among
cocaine-injecting populations.
2. What is the “causal lag” time period before a high
coverage NSP will lead to changes in HIV incidence or
prevalence in a population of PWID? With the exception
of the Bangladesh studies, all of the studies reported
here showed the changes in HIV or HCV infection inci-
dence or prevalence occurring within relatively short
time periods, typically 2 to 4 years. This does suggest
that implementation of high coverage of PWID and ster-
ile injection equipment may have effects within very
short time periods [39].
3. Is high-coverage of sterile injection equipment and
PWID in NSP programs in LIMCs as effective as NSPs
in high-income countries? A number of the studies
reported here do show rather substantial reductions in
HIV infection associated with the implementation of
high coverage NSPs. These are most clearly seen in the
studies that measured HIV incidence or estimated HIV
incidence (through prevalence among new injectors) or
used newly reported HIV cases. In the Estonia study, esti-
mated HIV incidence among new injectors fell by halfwhile in the Cross-Border studies (China and Vietnam),
estimated HIV incidence among new injectors fell by ap-
proximately three quarters or more. Even in the Bangla-
desh study, where HIV incidence was stable over eight
years at slightly over 1/100 person-years at risk, keeping
incidence this low over such an extended period can be
considered a prevention success.
For the NSP where newly reported HIV cases were used
as an outcome measure, the reductions ranged from 30%
to 93%. The data from Lithuania, however, showed a sub-
stantial increase in newly reported HIV cases in the last
year of the study period, coincident with a reduction in
syringes distributed during that year. There also has been
a recent outbreak of HIV among PWID in Greece that
was associated with low implementation of prevention
services [40,41].
Overall, the data in Table 1 suggests that NSPs in
LMIC show similar rates of reduction in HIV incidence
and prevalence as NSPs in high-income countries [8].
There are, however, examples from both high-income
and LMICs where NSPs have not prevented outbreaks
of HIV transmission among PWID [39,42].
With the possible exceptions of the estimated HIV
prevalence in Guangxi province China [27] and the num-
bers of newly reported HIV cases in Taiwan, the studies
reviewed here provide little evidence that the NSPs in
these locations are eliminating injecting-related HIV
transmission in the local population of PWID. Some of
the estimated incidence rates are still unacceptably high,
from 4/100 to 9/100 person-years at risk. Large-scale
“combined” HIV prevention programming, with not only
NSPs but also substance dependence treatment, HIV
counseling and testing and anti-retroviral treatment for
HIV seropositives may be required to reduce HIV trans-
mission to a level where zero new injecting-related infec-
tions becomes a realistic public health goal.
Conclusions
We conducted a systematic review of NSPs in low-and
middle-income countries. The inclusion criteria included
high coverage of at least 50% of local PWID participating
in the program or a minimum of 10 syringes distributed
per PWID per year, HIV and/or HCV biomarker outcome
data, and data for pre and post high-coverage implemen-
tation of the NSP. We were able to locate the needed data
for only 11 such NSPs. (Previous reviews had included
only two of these NSPs). The data suggest that a mini-
mum of 20 to 30 syringes per PWID per year may be
needed to affect HIV and/or HCV transmission in a popu-
lation of PWID. Reaching high coverage levels (between
20–30 syringes per PWID per year and at least 50% of the
PWID population) for NSP is very likely to be followed by
reductions in HIV and/or HCV infection in the local
population of PWID [16]. Additional prevention and
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order to eliminate HIV among PWID in low and middle
income countries.
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